Literature DB >> 35513723

CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.

Constance Baer1, Shunsuke Kimura2, Mitra S Rana3, Andrew B Kleist4,5, Tim Flerlage6, David J Feith7,8, Peter Chockley9, Wencke Walter1, Manja Meggendorfer1, Thomas L Olson7,8, HeeJin Cheon7,8,10, Kristine C Olson7,8, Aakrosh Ratan7,10,11, Martha-Lena Mueller1, James M Foran12, Laura J Janke13, Chunxu Qu13, Shaina N Porter14, Shondra M Pruett-Miller14, Ravi C Kalathur3, Claudia Haferlach1, Wolfgang Kern1, Elisabeth Paietta15, Paul G Thomas16, M Madan Babu17, Thomas P Loughran7,8, Ilaria Iacobucci18, Torsten Haferlach19, Charles G Mullighan20,21.   

Abstract

Chronic lymphoproliferative disorder of natural killer cells (CLPD-NK) is characterized by clonal expansion of natural killer (NK) cells where the underlying genetic mechanisms are incompletely understood. In the present study, we report somatic mutations in the chemokine gene CCL22 as the hallmark of a distinct subset of CLPD-NK. CCL22 mutations were enriched at highly conserved residues, mutually exclusive of STAT3 mutations and associated with gene expression programs that resembled normal CD16dim/CD56bright NK cells. Mechanistically, the mutations resulted in ligand-biased chemokine receptor signaling, with decreased internalization of the G-protein-coupled receptor (GPCR) for CCL22, CCR4, via impaired β-arrestin recruitment. This resulted in increased cell chemotaxis in vitro, bidirectional crosstalk with the hematopoietic microenvironment and enhanced NK cell proliferation in vivo in transgenic human IL-15 mice. Somatic CCL22 mutations illustrate a unique mechanism of tumor formation in which gain-of-function chemokine mutations promote tumorigenesis by biased GPCR signaling and dysregulation of microenvironmental crosstalk.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35513723      PMCID: PMC9117519          DOI: 10.1038/s41588-022-01059-2

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   41.307


  82 in total

1.  Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets.

Authors:  W G Morice; D Jevremovic; H Olteanu; A Roden; G Nowakowski; S Kroft; C A Hanson; P J Kurtin
Journal:  Leukemia       Date:  2010-01-28       Impact factor: 11.528

Review 2.  Human CD56bright NK Cells: An Update.

Authors:  Tatiana Michel; Aurélie Poli; Angelica Cuapio; Benjamin Briquemont; Gilles Iserentant; Markus Ollert; Jacques Zimmer
Journal:  J Immunol       Date:  2016-04-01       Impact factor: 5.422

3.  Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing.

Authors:  Samantha L Smith; Philippa R Kennedy; Kevin B Stacey; Jonathan D Worboys; Annie Yarwood; Seungmae Seo; Everardo Hegewisch Solloa; Brandon Mistretta; Sujash S Chatterjee; Preethi Gunaratne; Kimaada Allette; Ying-Chih Wang; Melissa Laird Smith; Robert Sebra; Emily M Mace; Amir Horowitz; Wendy Thomson; Paul Martin; Steve Eyre; Daniel M Davis
Journal:  Blood Adv       Date:  2020-04-14

Review 4.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

5.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

Review 6.  LGL leukemia: from pathogenesis to treatment.

Authors:  Thierry Lamy; Aline Moignet; Thomas P Loughran
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

Review 7.  T cell large granular lymphocyte leukemia and chronic NK lymphocytosis.

Authors:  Gregorio Barilà; Giulia Calabretto; Antonella Teramo; Cristina Vicenzetto; Vanessa Rebecca Gasparini; Gianpietro Semenzato; Renato Zambello
Journal:  Best Pract Res Clin Haematol       Date:  2019-06-22       Impact factor: 3.020

8.  CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.

Authors:  Julia A Wagner; Maximillian Rosario; Rizwan Romee; Melissa M Berrien-Elliott; Stephanie E Schneider; Jeffrey W Leong; Ryan P Sullivan; Brea A Jewell; Michelle Becker-Hapak; Timothy Schappe; Sara Abdel-Latif; Aaron R Ireland; Devika Jaishankar; Justin A King; Ravi Vij; Dennis Clement; Jodie Goodridge; Karl-Johan Malmberg; Hing C Wong; Todd A Fehniger
Journal:  J Clin Invest       Date:  2017-10-03       Impact factor: 14.808

9.  Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation.

Authors:  Gregorio Barilà; Antonella Teramo; Giulia Calabretto; Chiara Ercolin; Elisa Boscaro; Valentina Trimarco; Samuela Carraro; Matteo Leoncin; Cristina Vicenzetto; Anna Cabrelle; Monica Facco; Francesco Piazza; Gianpietro Semenzato; Renato Zambello
Journal:  Blood Cancer J       Date:  2018-06-05       Impact factor: 11.037

10.  Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?

Authors:  Edoardo Giussani; Andrea Binatti; Giulia Calabretto; Vanessa Rebecca Gasparini; Antonella Teramo; Cristina Vicenzetto; Gregorio Barilà; Monica Facco; Alessandro Coppe; Gianpietro Semenzato; Stefania Bortoluzzi; Renato Zambello
Journal:  Front Oncol       Date:  2021-01-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.